NCT01673737 - A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions

Neoplasm Malignant

Interventions

DRUG

SAR260301

Pharmaceutical form: film-coated tablets Route of administration: oral

DRUG

Vemurafenib

Pharmaceutical form: film-coated tablets Route of administration: oral

Trial Locations (4)

Investigational Site Number 840002, Houston

Investigational Site Number 840001, Boston

Investigational Site Number 840101, Boston

Investigational Site Number 124001, Toronto